PFNX.png
Pfenex Reports Second Quarter 2020 Results and Provides Business Update
August 06, 2020 16:05 ET | Pfenex, Inc.
Commercialization and launch of first royalty bearing products position company for next phase of growthMultiple U.S. health plans add Teriparatide Injection to their formulary upon its June 2020...
PFNX.png
Pfenex to Announce Second Quarter Financial Results on August 6
July 20, 2020 08:30 ET | Pfenex, Inc.
SAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second quarter ended June 30, 2020, after the market...
PFNX.png
Pfenex Announces Positive European CHMP Opinion for PF708 (EU Brand Name: Livogiva™) and New Partnership in Latin America, and Provides CRM197 Business Update
June 26, 2020 14:05 ET | Pfenex, Inc.
Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for Livogiva marks important first step toward marketing authorizationPfenex’s commercial partner Adalvo entered into...
PFNX.png
Pfenex Announces U.S. Commercial Launch of Teriparatide Injection
June 12, 2020 08:00 ET | Pfenex, Inc.
Pfenex’s commercialization partner Alvogen will lead launch and commercialization efforts in the United StatesThe first FDA-approved teriparatide with Forteo® 1-3 as the reference drug SAN DIEGO,...
PFNX.png
Pfenex to Participate in the William Blair Growth Stock Conference
June 05, 2020 09:00 ET | Pfenex, Inc.
SAN DIEGO, June 05, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that Eef Schimmelpennink, President and Chief Executive Officer, will participate in a fire side chat...
PFNX.png
Pfenex Reports First Quarter 2020 Results and Provides Business Update
May 07, 2020 16:05 ET | Pfenex, Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its proprietary protein production platform,...
PFNX.png
Pfenex to Announce First Quarter 2020 Financial Results on May 7
April 24, 2020 16:05 ET | Pfenex, Inc.
SAN DIEGO, April 24, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the first quarter ended March 31, 2020, after the market...
Pfenex.jpg
Pfenex Announces FDA Requests Additional Comparative Use Human Factors Data in Experienced Users in order to Complete PF708 Therapeutic Equivalence Determination
April 14, 2020 17:04 ET | Pfenex, Inc.
SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA), informed Alvogen Malta Operations Ltd., the...
Pfenex.jpg
Pfenex Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update
March 11, 2020 16:05 ET | Pfenex, Inc.
Alvogen is preparing for commercial launch of PF708 upon receiving FDA decision on therapeutic equivalence to Forteo® Jazz initiated a pivotal Phase 2/3 Study for FDA fast track designated PF743...
Pfenex.jpg
Pfenex to Announce Fourth Quarter and Year-End 2019 Financial Results on March 11
February 26, 2020 17:03 ET | Pfenex, Inc.
SAN DIEGO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the fourth quarter and year ended December 31, 2019,...